Tossicità epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC).

Translated title of the contribution: Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)

G. Vennarecci, G. M. Ettorre, M. Antonini, M. Maritti, P. Moricca, G. D'Offizzi, P. Narciso, M. T. Lonardo, A. Boschetto, F. Del Nonno, L. Perracchio, G. P. Palmieri, G. Visco, E. Santoro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OLT in HIV infected patients still remains a challenging option requiring a careful monitoring of patients for HCV reinfection, drug interactions and antiretroviral toxicity. Severe adverse events due to HAART have been already reported for post exposure prophylaxis in HIV infected patients. Here we report a case of liver graft toxicity related to HAART in a HIV-HCV co-infected patient (46 yrs-male) with associated a small HCC transplanted with a marginal liver graft. The patient had pre-OLT plasma HIV 1-RNA levels undetectable and CD4+ T-cell count of > 200 cells/microL for 6 months. At day 2 a severe graft dysfunction was observed (AST 1570 U/L, ALT 2180 U/L, BIL tot 8.3 mg/dL, BIL Dir 6.6 mg/dL and PT 35%--INR 2.5). Doppler scan showed hepatic artery always patient. Later the postoperative in-hospital course was complicated by tense ascites and severe cholestasis. Serum bilirubin reached 42 mg/dL in day 12. Hypertransaminasemia ended at day 15 while cholestasis ended after 46 days. Tacrolimus was reintroduced at day 7. A liver biopsy 10 after OLT showed severe intrahepatic cholestasis, centrolobular necrosis and macrovesicular steatosis (30%). The patient was discharged 48 days after OLT with good liver function. After seven months HIV-RNA is still undetectable and HAART has not been restarted. We believe that the early complications we observed may be attributed to a sudden increase in plasma concentration of antiretroviral drugs secondary to drug redistribution from peripheral tissues and hepatic clearance deficiency after OLT. Although a pre-OLT withdrawal of HAART seems unjustified a delayed re-introduction of HAART or the use of less hepatotoxic drugs may be advisable.

Original languageItalian
Pages (from-to)159-161
Number of pages3
JournalTumori
Volume89
Issue number4 Suppl
Publication statusPublished - Jul 2003

Fingerprint

Highly Active Antiretroviral Therapy
Coinfection
Liver Transplantation
HIV
Liver
Cholestasis
Transplants
Therapeutics
Post-Exposure Prophylaxis
Pharmaceutical Preparations
RNA
Intrahepatic Cholestasis
International Normalized Ratio
Hepatic Artery
Physiologic Monitoring
Tacrolimus
CD4 Lymphocyte Count
Drug Interactions
Bilirubin
Ascites

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tossicità epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC). / Vennarecci, G.; Ettorre, G. M.; Antonini, M.; Maritti, M.; Moricca, P.; D'Offizzi, G.; Narciso, P.; Lonardo, M. T.; Boschetto, A.; Del Nonno, F.; Perracchio, L.; Palmieri, G. P.; Visco, G.; Santoro, E.

In: Tumori, Vol. 89, No. 4 Suppl, 07.2003, p. 159-161.

Research output: Contribution to journalArticle

Vennarecci, G, Ettorre, GM, Antonini, M, Maritti, M, Moricca, P, D'Offizzi, G, Narciso, P, Lonardo, MT, Boschetto, A, Del Nonno, F, Perracchio, L, Palmieri, GP, Visco, G & Santoro, E 2003, 'Tossicità epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC).', Tumori, vol. 89, no. 4 Suppl, pp. 159-161.
Vennarecci, G. ; Ettorre, G. M. ; Antonini, M. ; Maritti, M. ; Moricca, P. ; D'Offizzi, G. ; Narciso, P. ; Lonardo, M. T. ; Boschetto, A. ; Del Nonno, F. ; Perracchio, L. ; Palmieri, G. P. ; Visco, G. ; Santoro, E. / Tossicità epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC). In: Tumori. 2003 ; Vol. 89, No. 4 Suppl. pp. 159-161.
@article{99e297a15ff9417c9b72f137b290f2ad,
title = "Tossicit{\`a} epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC).",
abstract = "OLT in HIV infected patients still remains a challenging option requiring a careful monitoring of patients for HCV reinfection, drug interactions and antiretroviral toxicity. Severe adverse events due to HAART have been already reported for post exposure prophylaxis in HIV infected patients. Here we report a case of liver graft toxicity related to HAART in a HIV-HCV co-infected patient (46 yrs-male) with associated a small HCC transplanted with a marginal liver graft. The patient had pre-OLT plasma HIV 1-RNA levels undetectable and CD4+ T-cell count of > 200 cells/microL for 6 months. At day 2 a severe graft dysfunction was observed (AST 1570 U/L, ALT 2180 U/L, BIL tot 8.3 mg/dL, BIL Dir 6.6 mg/dL and PT 35{\%}--INR 2.5). Doppler scan showed hepatic artery always patient. Later the postoperative in-hospital course was complicated by tense ascites and severe cholestasis. Serum bilirubin reached 42 mg/dL in day 12. Hypertransaminasemia ended at day 15 while cholestasis ended after 46 days. Tacrolimus was reintroduced at day 7. A liver biopsy 10 after OLT showed severe intrahepatic cholestasis, centrolobular necrosis and macrovesicular steatosis (30{\%}). The patient was discharged 48 days after OLT with good liver function. After seven months HIV-RNA is still undetectable and HAART has not been restarted. We believe that the early complications we observed may be attributed to a sudden increase in plasma concentration of antiretroviral drugs secondary to drug redistribution from peripheral tissues and hepatic clearance deficiency after OLT. Although a pre-OLT withdrawal of HAART seems unjustified a delayed re-introduction of HAART or the use of less hepatotoxic drugs may be advisable.",
author = "G. Vennarecci and Ettorre, {G. M.} and M. Antonini and M. Maritti and P. Moricca and G. D'Offizzi and P. Narciso and Lonardo, {M. T.} and A. Boschetto and {Del Nonno}, F. and L. Perracchio and Palmieri, {G. P.} and G. Visco and E. Santoro",
year = "2003",
month = "7",
language = "Italian",
volume = "89",
pages = "159--161",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4 Suppl",

}

TY - JOUR

T1 - Tossicità epatica acuta da terapia antiretrovirale (HAART) dopo trapianto di fegato in un paziente con coinfezione da HIV-HCV ed associato epatocarcinoma (HCC).

AU - Vennarecci, G.

AU - Ettorre, G. M.

AU - Antonini, M.

AU - Maritti, M.

AU - Moricca, P.

AU - D'Offizzi, G.

AU - Narciso, P.

AU - Lonardo, M. T.

AU - Boschetto, A.

AU - Del Nonno, F.

AU - Perracchio, L.

AU - Palmieri, G. P.

AU - Visco, G.

AU - Santoro, E.

PY - 2003/7

Y1 - 2003/7

N2 - OLT in HIV infected patients still remains a challenging option requiring a careful monitoring of patients for HCV reinfection, drug interactions and antiretroviral toxicity. Severe adverse events due to HAART have been already reported for post exposure prophylaxis in HIV infected patients. Here we report a case of liver graft toxicity related to HAART in a HIV-HCV co-infected patient (46 yrs-male) with associated a small HCC transplanted with a marginal liver graft. The patient had pre-OLT plasma HIV 1-RNA levels undetectable and CD4+ T-cell count of > 200 cells/microL for 6 months. At day 2 a severe graft dysfunction was observed (AST 1570 U/L, ALT 2180 U/L, BIL tot 8.3 mg/dL, BIL Dir 6.6 mg/dL and PT 35%--INR 2.5). Doppler scan showed hepatic artery always patient. Later the postoperative in-hospital course was complicated by tense ascites and severe cholestasis. Serum bilirubin reached 42 mg/dL in day 12. Hypertransaminasemia ended at day 15 while cholestasis ended after 46 days. Tacrolimus was reintroduced at day 7. A liver biopsy 10 after OLT showed severe intrahepatic cholestasis, centrolobular necrosis and macrovesicular steatosis (30%). The patient was discharged 48 days after OLT with good liver function. After seven months HIV-RNA is still undetectable and HAART has not been restarted. We believe that the early complications we observed may be attributed to a sudden increase in plasma concentration of antiretroviral drugs secondary to drug redistribution from peripheral tissues and hepatic clearance deficiency after OLT. Although a pre-OLT withdrawal of HAART seems unjustified a delayed re-introduction of HAART or the use of less hepatotoxic drugs may be advisable.

AB - OLT in HIV infected patients still remains a challenging option requiring a careful monitoring of patients for HCV reinfection, drug interactions and antiretroviral toxicity. Severe adverse events due to HAART have been already reported for post exposure prophylaxis in HIV infected patients. Here we report a case of liver graft toxicity related to HAART in a HIV-HCV co-infected patient (46 yrs-male) with associated a small HCC transplanted with a marginal liver graft. The patient had pre-OLT plasma HIV 1-RNA levels undetectable and CD4+ T-cell count of > 200 cells/microL for 6 months. At day 2 a severe graft dysfunction was observed (AST 1570 U/L, ALT 2180 U/L, BIL tot 8.3 mg/dL, BIL Dir 6.6 mg/dL and PT 35%--INR 2.5). Doppler scan showed hepatic artery always patient. Later the postoperative in-hospital course was complicated by tense ascites and severe cholestasis. Serum bilirubin reached 42 mg/dL in day 12. Hypertransaminasemia ended at day 15 while cholestasis ended after 46 days. Tacrolimus was reintroduced at day 7. A liver biopsy 10 after OLT showed severe intrahepatic cholestasis, centrolobular necrosis and macrovesicular steatosis (30%). The patient was discharged 48 days after OLT with good liver function. After seven months HIV-RNA is still undetectable and HAART has not been restarted. We believe that the early complications we observed may be attributed to a sudden increase in plasma concentration of antiretroviral drugs secondary to drug redistribution from peripheral tissues and hepatic clearance deficiency after OLT. Although a pre-OLT withdrawal of HAART seems unjustified a delayed re-introduction of HAART or the use of less hepatotoxic drugs may be advisable.

UR - http://www.scopus.com/inward/record.url?scp=0041379159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041379159&partnerID=8YFLogxK

M3 - Articolo

VL - 89

SP - 159

EP - 161

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4 Suppl

ER -